Home | Emory University

Infectious Diseases Clinical Research Consortium (IDCRC)

Infectious Diseases Clinical Research Consortium

Slide 1:
Slide 2:
Slide 3:
Slide 4:

The Infectious Diseases Clinical Research Consortium (IDCRC) and Vaccine and Treatment Evaluation Units (VTEUs) work in tandem with the National Institute of Allergy and Infectious Diseases (NIAID) as a coordinated national and global network of scientific experts working to develop and test vaccines and other therapies to combat infectious diseases.

About

The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.

IDCRC Active & Completed Studies

IDCRC study assessing meningococcal pentavalent (ACYWX) vaccine for infants in Africa shared with WHO; provides affordable protection against meningococcal meningitis

Researchers from the Infectious Diseases Clinical Research Consortium (IDCRC) provided an interim report of the Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine (DMID 20-0024) study’s nine-month infant group to the WHO Strategic Advisory Group of Experts (SAGE) on Immunization on September 26. The study results show that the pentavalent (NmCV-5 or MenFive®) vaccine is safe and highly immunogenic at 28 days post-vaccine.

COVID-19 Prevention Network

The CoVPN was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network; the HIV Prevention Trials Network; the Infectious Diseases Clinical Research Consortium; and the AIDS Clinical Trials Group.

More about the CoVPN

COVID-19 Prevention Network launches two research studies evaluating monoclonal antibodies

IDCRC Sites Across the Nation

View World Map

News from VTEU Trials

A Prospective Study of Key Correlates for Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2

Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial

Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration

Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case

IDCRC Leadership Group

IDCRC Vaccine & Treatment Evaluation Units (VTEUs)

IDCRC Concept Quick Stats

ICP Status

Approved: 51
Administratively Not Supported: 28
Not Approved: 49
EWG Review: 1
EWG Liaisons: 0
EMT Concurrence: 0
Withdrawn: 15
Hold: 0
Moved to Active Study: 2

EWG Assignment

COVID: 92
Respiratory: 26
Emerging Infections: 12
Enteric Infections: 7
Malaria/Topical Diseases: 13
STI: 14

ECP

EWG Review-In Process: 3
EMT Review: 2
Approved-moved to Prioritization: 3
Not Approved: 13
Approved-moved to Protocol Development: 10
Active Study: 10
EMT Vote: 0
Other: 10

IDCRC Citation Statement

Please include the following citation in any publications resulting from direct or indirect IDCRC support:

"Supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."

Publications